In addition, LOH of BRCA, as well as TP53 mutations, have been demonstrated as early events in high-grade serous carcinomas in patients with germline mutations; accordingly, mutations and/or loss of heterozygosity of TP53 and BRCA have been identified in early carcinomas and epithelial inclusions of the ovary [63, 64]. Here, TP53 is linked to serous adenocarcinoma.